WENA vs. ATNM, SCYX, DRRX, GRTS, BLRX, BRNS, PRPH, RPHM, RLYB, and ANEB
Should you be buying ANEW Medical stock or one of its competitors? The main competitors of ANEW Medical include Actinium Pharmaceuticals (ATNM), SCYNEXIS (SCYX), DURECT (DRRX), Gritstone bio (GRTS), BioLineRx (BLRX), Barinthus Biotherapeutics (BRNS), ProPhase Labs (PRPH), Reneo Pharmaceuticals (RPHM), Rallybio (RLYB), and Anebulo Pharmaceuticals (ANEB). These companies are all part of the "pharmaceutical products" industry.
Actinium Pharmaceuticals (NYSE:ATNM) and ANEW Medical (NASDAQ:WENA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, community ranking, valuation and institutional ownership.
Actinium Pharmaceuticals received 3 more outperform votes than ANEW Medical when rated by MarketBeat users.
ANEW Medical has lower revenue, but higher earnings than Actinium Pharmaceuticals.
Actinium Pharmaceuticals currently has a consensus price target of $11.40, suggesting a potential upside of 540.45%. Given Actinium Pharmaceuticals' higher possible upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than ANEW Medical.
In the previous week, Actinium Pharmaceuticals had 1 more articles in the media than ANEW Medical. MarketBeat recorded 2 mentions for Actinium Pharmaceuticals and 1 mentions for ANEW Medical. ANEW Medical's average media sentiment score of 0.33 beat Actinium Pharmaceuticals' score of 0.00 indicating that ANEW Medical is being referred to more favorably in the news media.
ANEW Medical's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.
27.5% of Actinium Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.1% of ANEW Medical shares are owned by institutional investors. 4.0% of Actinium Pharmaceuticals shares are owned by insiders. Comparatively, 2.0% of ANEW Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Actinium Pharmaceuticals beats ANEW Medical on 7 of the 10 factors compared between the two stocks.
Get ANEW Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for WENA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WENA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
ANEW Medical Competitors List
Related Companies and Tools